1. Home
  2. DUO vs TCRT Comparison

DUO vs TCRT Comparison

Compare DUO & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DUO

Fangdd Network Group Ltd.

HOLD

Current Price

$1.59

Market Cap

7.5M

Sector

Finance

ML Signal

HOLD

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

HOLD

Current Price

$2.98

Market Cap

7.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DUO
TCRT
Founded
2011
1998
Country
China
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
7.2M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
DUO
TCRT
Price
$1.59
$2.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
66.1K
46.9K
Earning Date
03-13-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$56,189,313.00
$6,000.00
Revenue This Year
N/A
$5,680,500.00
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
48.30
N/A
52 Week Low
$1.24
$1.31
52 Week High
$11.46
$6.20

Technical Indicators

Market Signals
Indicator
DUO
TCRT
Relative Strength Index (RSI) 44.25 43.78
Support Level $1.54 $2.60
Resistance Level $1.68 $4.04
Average True Range (ATR) 0.09 0.28
MACD 0.01 -0.06
Stochastic Oscillator 40.00 26.39

Price Performance

Historical Comparison
DUO
TCRT

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.

Share on Social Networks: